Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ginkgo Diterpene Lactone Meglumine Injection + Aspirin in Acute Ischemic Stroke
NCT05531942Phase 3Unknown
- Sponsor
- Yueyang Hospital of Integrated Traditional Chinese and Western Medicine
- Start
- Jan 2021
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Ginkgo diterpene lactone meglumine in ischemic stroke (2 arms), sponsored by Yueyang Hospital of Integrated Traditional Chinese and Western Medicine. Primary endpoint: National Institute of Health Stroke Scale at 90 days. Status: unknown.
02
Drugs
Ginkgo diterpene lactone meglumine
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT05531942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05531942.